A secretive biotech company has positioned itself to potentially earn billions in revenue with the planned release of a new technology that could help prevent millions of strokes with a simple test that is affordable, non-invasive and accessible to the average American. A Multi-Billion-Dollar Problem with a $49,000 Answer Until now, there has been no cost-effective way to screen for Ischemia, the leading indicator of a stroke, which costs the U.S. government alone tens of billions of dollars a year. That could be about to change, thanks to a breakthrough…
Read Full Article Here